The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
about
Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting.Refining estimates of prescription durations by using observed covariates in pharmacoepidemiologic databases: Necessary refinements to stimulate alternative approaches.
P2860
The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The case for dosing dabigatran ...... improve the benefit-risk ratio
@ast
The case for dosing dabigatran ...... improve the benefit-risk ratio
@en
The case for dosing dabigatran ...... improve the benefit-risk ratio
@nl
type
label
The case for dosing dabigatran ...... improve the benefit-risk ratio
@ast
The case for dosing dabigatran ...... improve the benefit-risk ratio
@en
The case for dosing dabigatran ...... improve the benefit-risk ratio
@nl
prefLabel
The case for dosing dabigatran ...... improve the benefit-risk ratio
@ast
The case for dosing dabigatran ...... improve the benefit-risk ratio
@en
The case for dosing dabigatran ...... improve the benefit-risk ratio
@nl
P2093
P2860
P3181
P356
P1476
The case for dosing dabigatran ...... improve the benefit-risk ratio
@en
P2093
Apostolos Safouris
Georgios Tsivgoulis
John Parissis
Nikos Triantafyllou
P2860
P304
P3181
P356
10.1177/1756285615601360
P407
P577
2015-11-01T00:00:00Z